Retrospective Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Apr 7, 2018; 24(13): 1464-1477
Published online Apr 7, 2018. doi: 10.3748/wjg.v24.i13.1464
Table 1 Clinical characteristics of enrolled patients
CDUCControl
n151413
Age, mean ± SD, yr37.7 ± 13.037.5 ± 17.139.8 ± 14.3
Sex, male/female11/47/710/3
Disease duration in months, median (range)10 (3-48)30 (2-93)-
Smoking habits4 (26.7)1 (7.1)2 (15.4)
Abdominal surgery4 (26.7)00
Montreal A (age of onset)
A1 (< 17)1 (6.7)--
A2 (17-40)7 (46.7)--
A3 (> 40)7 (46.7)--
Montreal L (location)
L1 (ileal)8 (53.3)--
L2 (colonic)1 (6.7)--
L3 (ileocolonic)6 (40)--
L4 (upper gastrointestinal tract)0--
Montreal B (behavior)
B1(nonstricturing, nonpenetrating)8 (53.3)--
B2 (stricturing)6 (40)--
B3 (penetrating)1 (6.7)--
p (perianal disease)4 (26.7)--
Montreal
E1 ulcerative proctitis-4 (28.6)-
E2 left sided ulcerative colitis-5 (35.7)-
E3 extensive ulcerative colitis-5 (35.7)-
CDAI score
< 1504 (26.7)--
150-2205 (33.3)--
221-4506 (40)--
> 4500--
Mayo score
0-2-0-
3-5-7 (50.0)-
6-10-5 (35.7)-
11-12-2 (14.3)-
Therapy
5-ASA14 (93.3)14 (100)-
Azathioprine2 (13.3)0-
Steroids1 (6.7)6 (42.9)-
Infliximab00-